Symbols / SKYE $0.70 +0.11% Skye Bioscience, Inc.
SKYE Chart
About
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 23.33M |
| Enterprise Value | -2.17M | Income | -55.92M | Sales | — |
| Book/sh | 0.60 | Cash/sh | 0.77 | Dividend Yield | — |
| Payout | 0.00% | Employees | 12 | IPO | — |
| P/E | — | Forward P/E | -0.65 | PEG | — |
| P/S | — | P/B | 1.16 | P/C | — |
| EV/EBITDA | 0.04 | EV/Sales | — | Quick Ratio | 3.14 |
| Current Ratio | 3.30 | Debt/Eq | 1.37 | LT Debt/Eq | — |
| EPS (ttm) | -1.41 | EPS next Y | -1.07 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -71.93% |
| ROE | -126.85% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 33.38M |
| Shs Float | 21.20M | Short Float | 6.84% | Short Ratio | 1.44 |
| Short Interest | — | 52W High | 5.75 | 52W Low | 0.57 |
| Beta | 2.87 | Avg Volume | 583.84K | Volume | 19.37K |
| Target Price | $8.25 | Recom | Buy | Prev Close | $0.70 |
| Price | $0.70 | Change | 0.11% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-30 | init | HC Wainwright & Co. | — → Buy | $20 |
| 2025-08-15 | init | Evercore ISI Group | — → Outperform | $10 |
| 2025-06-24 | reit | JMP Securities | Market Outperform → Market Outperform | $15 |
| 2025-03-21 | main | Craig-Hallum | Buy → Buy | $14 |
| 2025-03-21 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $15 |
| 2025-02-28 | init | William Blair | — → Outperform | — |
| 2024-09-30 | init | Scotiabank | — → Sector Outperform | $20 |
| 2024-09-20 | reit | Piper Sandler | Overweight → Overweight | $20 |
| 2024-09-20 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-09-10 | init | JMP Securities | — → Market Outperform | $15 |
| 2024-09-09 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-09-06 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-08-27 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-07-09 | init | Craig-Hallum | — → Buy | $18 |
| 2024-07-01 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-06-18 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-06-17 | reit | Cantor Fitzgerald | Overweight → Overweight | $14 |
| 2024-05-23 | init | Cantor Fitzgerald | — → Overweight | $21 |
| 2024-04-12 | init | Oppenheimer | — → Outperform | $25 |
| 2024-03-14 | reit | Piper Sandler | Overweight → Overweight | $20 |
- Director at Skye Bioscience (NASDAQ: SKYE) receives 75,000-share stock option grant - Stock Titan hu, 02 Apr 2026 22
- Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development - GlobeNewswire hu, 02 Apr 2026 11
- Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral - Investing.com Wed, 11 Mar 2026 07
- Skye Bioscience (SKYE) director awarded 75,000 stock options at $0.6150 - Stock Titan hu, 02 Apr 2026 22
- Skye Bioscience (SKYE) director receives 75,000 stock options at $0.615 strike - Stock Titan hu, 02 Apr 2026 22
- Citizens reiterates Skye Bioscience stock rating on weight loss data - Investing.com Wed, 11 Mar 2026 07
- Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire ue, 10 Mar 2026 07
- Skye Bioscience (SKYE) director Paul A. Grayson receives 75,000 stock options - Stock Titan hu, 02 Apr 2026 22
- SKYE SEC Filings - Skye Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan Sun, 05 Apr 2026 15
- Skye tests higher nimacimab doses ahead of Phase 2b obesity combo - Stock Titan hu, 02 Apr 2026 11
- Skye Bioscience (SKYE) reprices 2.42M options and taps John Sharp as CFO - Stock Titan Fri, 03 Apr 2026 20
- Director at Skye Bioscience (SKYE) awarded 75,000 stock options at $0.615 - Stock Titan hu, 02 Apr 2026 22
- [Form 3/A] Skye Bioscience, Inc. Amended Initial Statement of Beneficial Ownership - Stock Titan hu, 02 Apr 2026 22
- Skye Bioscience (SKYE) CSO updates option awards with repricing and new grants - Stock Titan hu, 02 Apr 2026 22
- Skye Bioscience (SKYE) reprices CEO stock options to $0.615 strike - Stock Titan hu, 02 Apr 2026 22
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
58.16
+59.67%
|
36.43
+166.44%
|
13.67
+12.93%
|
12.11
|
| Research And Development |
|
42.36
+126.51%
|
18.70
+221.36%
|
5.82
-3.20%
|
6.01
|
| Selling General And Administration |
|
15.80
-10.85%
|
17.73
+125.74%
|
7.85
+28.84%
|
6.09
|
| General And Administrative Expense |
|
15.80
-10.85%
|
17.73
+125.74%
|
7.85
+28.84%
|
6.09
|
| Other Gand A |
|
15.80
-10.85%
|
17.73
+125.74%
|
7.85
+28.84%
|
6.09
|
| Total Expenses |
|
58.16
+59.67%
|
36.43
+166.44%
|
13.67
+12.93%
|
12.11
|
| Operating Income |
|
-58.16
-59.67%
|
-36.43
-166.44%
|
-13.67
-12.93%
|
-12.11
|
| Total Operating Income As Reported |
|
-58.16
-92.64%
|
-30.19
+13.08%
|
-34.74
-89.69%
|
-18.31
|
| EBITDA |
|
-55.20
-118.25%
|
-25.29
+30.94%
|
-36.62
-95.87%
|
-18.70
|
| Normalized EBITDA |
|
-55.56
-68.95%
|
-32.88
-121.59%
|
-14.84
-22.70%
|
-12.09
|
| Reconciled Depreciation |
|
0.72
+142.22%
|
0.30
+140.35%
|
0.12
+8.05%
|
0.11
|
| EBIT |
|
-55.92
-118.53%
|
-25.59
+30.36%
|
-36.74
-95.33%
|
-18.81
|
| Total Unusual Items |
|
0.36
-95.25%
|
7.59
+134.86%
|
-21.78
-229.89%
|
-6.60
|
| Total Unusual Items Excluding Goodwill |
|
0.36
-95.25%
|
7.59
+134.86%
|
-21.78
-229.89%
|
-6.60
|
| Special Income Charges |
|
0.36
-95.25%
|
7.59
+134.86%
|
-21.78
-226.93%
|
-6.66
|
| Other Special Charges |
|
—
|
-6.23
-129.60%
|
21.06
+239.44%
|
6.21
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
0.41
-10.33%
|
0.46
|
| Write Off |
|
—
|
—
|
—
|
0.46
|
| Net Income |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Pretax Income |
|
-55.92
-110.56%
|
-26.56
+29.45%
|
-37.64
-93.28%
|
-19.47
|
| Net Non Operating Interest Income Expense |
|
1.88
-17.35%
|
2.28
+382.71%
|
-0.81
-5.21%
|
-0.77
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
0.97
+7.85%
|
0.90
+35.17%
|
0.66
|
| Net Interest Income |
|
1.88
-17.35%
|
2.28
+382.71%
|
-0.81
-5.21%
|
-0.77
|
| Interest Expense |
|
0.00
-100.00%
|
0.97
+7.85%
|
0.90
+35.17%
|
0.66
|
| Interest Income Non Operating |
|
1.88
-42.27%
|
3.26
+3164.36%
|
0.10
+425.87%
|
0.02
|
| Interest Income |
|
1.88
-42.27%
|
3.26
+3164.36%
|
0.10
+425.87%
|
0.02
|
| Other Income Expense |
|
0.36
-95.25%
|
7.59
+132.77%
|
-23.16
-250.84%
|
-6.60
|
| Other Non Operating Income Expenses |
|
-0.00
+77.18%
|
-0.00
+99.84%
|
-1.38
|
—
|
| Gain On Sale Of Security |
|
—
|
—
|
0.00
-99.99%
|
0.06
|
| Gain On Sale Of Business |
|
—
|
0.00
+100.00%
|
-0.41
+10.33%
|
-0.46
|
| Tax Provision |
|
0.01
-46.38%
|
0.01
+179.75%
|
0.00
-46.60%
|
0.01
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.08
-95.25%
|
1.59
+134.86%
|
-4.57
-229.89%
|
-1.39
|
| Net Income Including Noncontrolling Interests |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Net Income From Continuing Operation Net Minority Interest |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Net Income From Continuing And Discontinued Operation |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Net Income Continuous Operations |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Normalized Income |
|
-56.21
-72.60%
|
-32.57
-59.33%
|
-20.44
-43.27%
|
-14.27
|
| Net Income Common Stockholders |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Diluted EPS |
|
-1.41
-93.15%
|
-0.73
+86.41%
|
-5.37
+38.77%
|
-8.77
|
| Basic EPS |
|
-1.41
-93.15%
|
-0.73
+86.41%
|
-5.37
+38.77%
|
-8.77
|
| Basic Average Shares |
|
39.66
+8.70%
|
36.49
+420.79%
|
7.01
+215.43%
|
2.22
|
| Diluted Average Shares |
|
39.66
+8.70%
|
36.49
+420.79%
|
7.01
+215.43%
|
2.22
|
| Diluted NI Availto Com Stockholders |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Gain On Sale Of PPE |
|
0.36
-73.44%
|
1.36
+542.36%
|
-0.31
|
0.00
|
| Total Other Finance Cost |
|
—
|
0.02
+81.57%
|
0.01
-92.55%
|
0.12
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
28.31
-61.09%
|
72.76
+509.39%
|
11.94
+31.05%
|
9.11
|
| Current Assets |
|
27.09
-61.75%
|
70.83
+507.92%
|
11.65
+30.27%
|
8.94
|
| Cash Cash Equivalents And Short Term Investments |
|
25.74
-62.38%
|
68.42
+5345.15%
|
1.26
+0.96%
|
1.24
|
| Cash And Cash Equivalents |
|
5.88
-91.40%
|
68.42
+5345.15%
|
1.26
+0.96%
|
1.24
|
| Cash Financial |
|
—
|
—
|
1.26
+0.96%
|
1.24
|
| Other Short Term Investments |
|
19.85
|
0.00
|
—
|
—
|
| Receivables |
|
0.01
+106.79%
|
0.01
-96.80%
|
0.16
+113.49%
|
0.07
|
| Taxes Receivable |
|
0.01
+106.79%
|
0.01
-96.80%
|
0.16
+113.49%
|
0.07
|
| Prepaid Assets |
|
1.33
-39.40%
|
2.20
+267.95%
|
0.60
-32.25%
|
0.88
|
| Restricted Cash |
|
—
|
0.00
-100.00%
|
9.08
+198157.69%
|
0.00
|
| Assets Held For Sale Current |
|
—
|
—
|
0.00
-100.00%
|
6.43
|
| Other Current Assets |
|
0.01
-93.35%
|
0.21
-62.88%
|
0.56
+82.39%
|
0.31
|
| Total Non Current Assets |
|
1.22
-37.03%
|
1.94
+568.76%
|
0.29
+73.03%
|
0.17
|
| Net PPE |
|
1.17
-38.09%
|
1.88
+569.35%
|
0.28
+76.84%
|
0.16
|
| Gross PPE |
|
1.94
-8.36%
|
2.12
+461.76%
|
0.38
+136.85%
|
0.16
|
| Accumulated Depreciation |
|
-0.77
-231.31%
|
-0.23
-144.69%
|
-0.10
|
—
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
0.04
-50.74%
|
0.09
|
| Machinery Furniture Equipment |
|
1.65
+0.38%
|
1.64
+1216.45%
|
0.12
|
—
|
| Other Properties |
|
0.27
-40.73%
|
0.45
+89.03%
|
0.24
+234.29%
|
0.07
|
| Leases |
|
0.02
+0.00%
|
0.02
+71.41%
|
0.01
|
—
|
| Other Non Current Assets |
|
0.05
+0.00%
|
0.05
+548.81%
|
0.01
+0.00%
|
0.01
|
| Total Liabilities Net Minority Interest |
|
8.29
+79.73%
|
4.61
-67.23%
|
14.07
+16.12%
|
12.12
|
| Current Liabilities |
|
8.21
+89.11%
|
4.34
-68.79%
|
13.90
+14.70%
|
12.12
|
| Payables And Accrued Expenses |
|
5.38
+49.19%
|
3.61
-57.50%
|
8.49
+219.82%
|
2.65
|
| Payables |
|
2.03
+257.21%
|
0.57
-40.50%
|
0.96
-49.40%
|
1.89
|
| Accounts Payable |
|
2.03
+257.21%
|
0.57
-40.50%
|
0.96
-46.70%
|
1.79
|
| Other Payable |
|
—
|
—
|
—
|
0.06
|
| Current Accrued Expenses |
|
3.35
+10.22%
|
3.04
-59.66%
|
7.53
+886.97%
|
0.76
|
| Current Debt And Capital Lease Obligation |
|
0.19
+3.96%
|
0.18
-95.89%
|
4.44
+124.16%
|
1.98
|
| Current Debt |
|
—
|
—
|
4.37
+129.64%
|
1.90
|
| Other Current Borrowings |
|
—
|
—
|
4.37
+129.64%
|
1.90
|
| Current Capital Lease Obligation |
|
0.19
+3.96%
|
0.18
+153.24%
|
0.07
-8.47%
|
0.08
|
| Other Current Liabilities |
|
2.63
+379.64%
|
0.55
-43.36%
|
0.97
-87.04%
|
7.48
|
| Total Non Current Liabilities Net Minority Interest |
|
0.08
-69.25%
|
0.27
+59.53%
|
0.17
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.08
-69.25%
|
0.27
+59.53%
|
0.17
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.08
-69.25%
|
0.27
+59.53%
|
0.17
|
0.00
|
| Stockholders Equity |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Common Stock Equity |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Capital Stock |
|
0.03
+7.76%
|
0.03
+150.83%
|
0.01
+237.96%
|
0.00
|
| Common Stock |
|
0.03
+7.76%
|
0.03
+150.83%
|
0.01
+237.96%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
33.38
+7.76%
|
30.97
+150.82%
|
12.35
+237.95%
|
3.65
|
| Ordinary Shares Number |
|
33.38
+7.76%
|
30.97
+150.82%
|
12.35
+237.95%
|
3.65
|
| Additional Paid In Capital |
|
206.87
+3.92%
|
199.07
+94.71%
|
102.24
+60.43%
|
63.73
|
| Retained Earnings |
|
-186.87
-42.71%
|
-130.95
-25.45%
|
-104.38
-56.41%
|
-66.74
|
| Total Equity Gross Minority Interest |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Total Capitalization |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Working Capital |
|
18.89
-71.59%
|
66.49
+3054.83%
|
-2.25
+29.14%
|
-3.18
|
| Invested Capital |
|
20.02
-70.62%
|
68.15
+2942.24%
|
2.24
+302.87%
|
-1.10
|
| Total Debt |
|
0.27
-39.94%
|
0.46
-90.13%
|
4.62
+132.80%
|
1.98
|
| Net Debt |
|
—
|
—
|
3.12
+372.55%
|
0.66
|
| Capital Lease Obligations |
|
0.27
-39.94%
|
0.46
+87.28%
|
0.24
+209.11%
|
0.08
|
| Net Tangible Assets |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Tangible Book Value |
|
20.02
-70.62%
|
68.15
+3296.88%
|
-2.13
+29.13%
|
-3.01
|
| Dueto Related Parties Current |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Interest Payable |
|
—
|
0.00
-100.00%
|
0.36
+2181.38%
|
0.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-43.06
-70.63%
|
-25.24
-80.89%
|
-13.95
-9.48%
|
-12.74
|
| Cash Flow From Continuing Operating Activities |
|
-43.06
-70.63%
|
-25.24
-80.89%
|
-13.95
-9.48%
|
-12.74
|
| Net Income From Continuing Operations |
|
-55.92
-110.50%
|
-26.57
+29.43%
|
-37.64
-93.23%
|
-19.48
|
| Depreciation Amortization Depletion |
|
0.72
+142.22%
|
0.30
+140.35%
|
0.12
+8.05%
|
0.11
|
| Depreciation And Amortization |
|
0.72
+142.22%
|
0.30
+140.35%
|
0.12
+8.05%
|
0.11
|
| Other Non Cash Items |
|
—
|
-3.64
-330.50%
|
1.58
-76.86%
|
6.82
|
| Stock Based Compensation |
|
7.77
-6.61%
|
8.32
+742.27%
|
0.99
+56.99%
|
0.63
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
0.33
|
0.00
|
—
|
| Operating Gains Losses |
|
-0.36
+73.23%
|
-1.35
-106.28%
|
21.47
+36050.49%
|
-0.06
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-0.00
+99.99%
|
-0.06
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
0.00
+100.00%
|
-0.05
|
0.00
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
-100.00%
|
21.22
|
0.00
|
| Change In Working Capital |
|
4.73
+280.01%
|
-2.63
-460.14%
|
-0.47
+38.40%
|
-0.76
|
| Change In Prepaid Assets |
|
-0.30
-3832.60%
|
-0.01
-100.97%
|
0.80
+26929.69%
|
-0.00
|
| Change In Payables And Accrued Expense |
|
1.55
+314.94%
|
-0.72
-556.68%
|
-0.11
-111.52%
|
0.95
|
| Change In Accrued Expense |
|
0.16
+215.06%
|
-0.13
-122.81%
|
0.59
+283.58%
|
0.15
|
| Change In Payable |
|
1.40
+337.91%
|
-0.59
+16.36%
|
-0.70
-187.69%
|
0.80
|
| Change In Account Payable |
|
1.40
+337.91%
|
-0.59
+16.36%
|
-0.70
-187.69%
|
0.80
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
1.36
+192.93%
|
-1.46
-198.87%
|
-0.49
-532.91%
|
0.11
|
| Change In Other Current Liabilities |
|
2.13
+584.68%
|
-0.44
+34.10%
|
-0.67
+63.53%
|
-1.83
|
| Investing Cash Flow |
|
-19.50
-7839.37%
|
-0.25
-103.72%
|
6.60
+26.50%
|
5.21
|
| Cash Flow From Continuing Investing Activities |
|
-19.50
-7839.37%
|
-0.25
-103.72%
|
6.60
+26.50%
|
5.21
|
| Net PPE Purchase And Sale |
|
0.35
+244.31%
|
-0.25
-104.45%
|
5.52
+19771.12%
|
-0.03
|
| Purchase Of PPE |
|
-0.01
+99.61%
|
-1.60
-12681.09%
|
-0.01
+55.27%
|
-0.03
|
| Sale Of PPE |
|
0.36
-73.44%
|
1.36
-75.45%
|
5.53
|
0.00
|
| Capital Expenditure |
|
-0.01
+99.61%
|
-1.60
-12681.09%
|
-0.01
+55.27%
|
-0.03
|
| Net Investment Purchase And Sale |
|
-19.85
|
0.00
|
—
|
—
|
| Purchase Of Investment |
|
-19.85
|
0.00
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
1.08
-79.46%
|
5.24
|
| Financing Cash Flow |
|
0.03
-99.96%
|
83.56
+408.18%
|
16.44
+7975.36%
|
-0.21
|
| Cash Flow From Continuing Financing Activities |
|
0.03
-99.96%
|
83.56
+408.18%
|
16.44
+7975.36%
|
-0.21
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
-100.00%
|
4.71
+2336.82%
|
-0.21
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
4.97
+630.46%
|
0.68
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-0.26
+70.92%
|
-0.89
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
0.68
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-0.26
+70.92%
|
-0.89
|
| Net Long Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-0.26
-23.05%
|
-0.21
|
| Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
4.97
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
-0.01
+99.02%
|
-0.62
|
| Net Short Term Debt Issuance |
|
—
|
0.00
-100.00%
|
4.97
|
0.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
83.56
+612.03%
|
11.73
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.03
+426.36%
|
0.01
|
0.00
-100.00%
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
-0.01
|
—
|
| Changes In Cash |
|
-62.53
-207.67%
|
58.08
+539.11%
|
9.09
+217.43%
|
-7.74
|
| Beginning Cash Position |
|
68.42
+561.88%
|
10.34
+727.52%
|
1.25
-86.10%
|
8.99
|
| End Cash Position |
|
5.88
-91.40%
|
68.42
+561.88%
|
10.34
+727.52%
|
1.25
|
| Free Cash Flow |
|
-43.07
-60.46%
|
-26.84
-92.21%
|
-13.96
-9.34%
|
-12.77
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.43
+118.47%
|
0.20
-40.53%
|
0.33
|
| Income Tax Paid Supplemental Data |
|
0.01
+3.85%
|
0.01
+44.44%
|
0.00
-46.60%
|
0.01
|
| Change In Interest Payable |
|
0.00
+100.00%
|
-0.36
-200.00%
|
0.36
+326.77%
|
-0.16
|
| Common Stock Issuance |
|
0.00
-100.00%
|
83.56
+612.03%
|
11.73
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
83.56
+612.03%
|
11.73
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-03 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 8-K2026-03-19 View
- 8-K2026-03-10 View
- 10-K2026-03-10 View
- 8-K2026-02-20 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|